Abstract: Objective To explore the correlation between iodine intake and BRAF V600E gene mutation and the development of thyroid papillary carcinoma （PTC）, to provide a scientific basis for reasonable iodine intake. Methods From January 2016 to January 2019, a total of 124 patients with PTC admitted to the Department of Endocrinology, The First Affiliated Hospital of Xingtai Medical College were selected as the observation group. Meanwhile, the BRAF V600E mutation gene was detected. At the same time, 120 normal thyroid function subjects in the same area were selected as the control group, and a comparative study was conducted in the same way. Results The urinary iodine value （MUI） level of the observation group PTC was （342.8±27.5） μg/L, significantly higher than that in the control group （187.9±17.7） μg/L（P<0.05）. Among the 124 PTC patients, 80 cases of BRAF V600E gene mutation were found （64.5%）, significantly higher than that in the control group （n=0） （P<0.05）. Mutation genotype in urine iodine value comparison between groups, iodine deficiency group, iodine enough, iodine adequate, and iodine excess group of BRAF V600E mutation rate were 16.7%, 50.0%, 64.9%, and 16.7% respectively, BRAF V600E mutation rate associated with urinary iodine value increases, the more significant difference between groups （P=0.004）. Conclusions There was a high probability of genetic mutation of BRAF V600E in PTC patients, while high iodine intake was a significant risk factor for BRAF V600E gene mutation, and there might be a correlation with PTC incidence.